ClinicalTrials.gg
CompletedNCT06286033Updated Dec 23, 2025

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

A Phase 1 interventional study of AG-181 and Placebo in Healthy Volunteers, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to participate in the study, give written , and comply with the study restrictions.
  • in the range of 18.0 to 30.0 kilograms per square meter (kg/m\^2).
  • Weight ≥ 50 kilograms (kg) at screening.
  • Healthy status as defined by the absence of evidence of any , in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead (ECG), hematology, blood chemistry, serology, and urinalysis.
  • Ability and willingness to refrain from alcohol-, caffeine-, and methylxanthine-containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 72 hours (3 days) before administration of the first dose of study drug through follow-up.
  • All values for hematology and clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations, as judged by the Investigator.
  • For women of child bearing potential ()*, have a negative serum pregnancy test at Screening and during admission to the clinic.

    a. *WOCBP are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally . WOCBP must use an acceptable method of from Screening and until 14 days or 5 half-lives of AG-181, whichever is longer, after last dose of AG-181. WOCBP using hormonal contraception as a highly effective form of contraception must also use an acceptable barrier method.

  • Male participants with female partners of childbearing potential must use a condom during treatment and for 14 days or 5 half-lives of AG-181, whichever is longer, after last dose of AG-181.
  • Male participants must agree not to donate sperm during the study and for 14 days or 5 half-lives of AG-181, whichever is longer, after the last dose of study drug.
  • Postmenopausal women are women who have not menstruated at all for at least the 12 months before providing informed consent and who have an elevated follicle-stimulating hormone (FSH) level indicative of menopause during screening.
  • Participants must have discontinued use of prescription drugs (including topical skin preparations other than nonsteroidal/nonantibiotic nonprescription moisturizers) within 2 weeks or 5 half-lives (whichever is longer) of the first dose of study drug, and over-the-counter (OTC) medication (excluding routine vitamins) within 7 days of the first dose of study drug, unless agreed as not clinically relevant by the Investigator and Medical Monitor (or designee).

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 14 days or 5 half-lives of AG-181, whichever is longer, after last dose of study drug.
  • Males with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 14 days or 5 half-lives of AG-181, whichever is longer, after last dose of study drug.
  • Prior exposure to AG-181.
  • Use of any drug or device within 30 days before administration of the first dose of study drug.
  • Any disease which, in the opinion of the Investigator, poses an unacceptable risk to the participants.
  • history of, including treatment within an Emergency Department for, any drug sensitivity, drug allergy, or food allergy, as determined by the Investigator (such as anaphylaxis, hepatotoxicity, or treatment with or epinephrine).
  • \<90 milliliters per minute (mL/min) (by Cockcroft-Gault formula) at screening.
  • > (ULN) or alanine aminotransferase >ULN at screening.
  • Use of tobacco or nicotine products in the 48 hours (2 days) prior to administration of the first dose of study drug.
  • Strenuous activity, sunbathing, and contact sports within 48 hours (2 days) prior to administration of the first dose of study drug.
  • History of donation of more than 450 milliliters (mL) of blood within 60 days prior to administration of the first dose of study drug.
  • Plasma or donation within 7 days prior to administration of the first dose of study drug.
  • History within the 12 months before Screening of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink=12 ounce (oz) beer, 5 oz wine, and 1.5 oz spirits). Alcohol consumption will be prohibited 72 hours prior to administration of the first dose of study drug and until discharge.
  • Positive test result for surface antigen (HBsAg), virus (HCV) antibodies, or anti- (HIV) 1 and 2 antibodies at screening.
  • Consumption of any nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) within 14 days prior to administration of the first dose of study drug.
  • Positive alcohol or drug screen (cannabinoids, amphetamines, methamphetamines, 3,4-methylenedioxy-N-methylamphetamine [ecstasy], opiates, methadone, oxycodone, phencyclidine, cocaine, cotinine, benzodiazepines, and barbiturates) at screening or admission to the clinical facility.
  • Prolonged heart rate- interval (QTc) [heart rate-corrected QT interval by Fridericia's formula (QTcF) >450 milliseconds (msec)] during screening and prior to first dose of study drug.
  • History of long-QT syndrome, torsade de pointes, or any risk factors for torsades de pointes in the opinion of the investigator.
  • A history in any family member of any of the following: sudden cardiac death, unexplained death, long-QT syndrome, or death from a primary dysrhythmia potentially associated with QT prolongation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Part 1: Single Ascending Dose (SAD)

    Participants will receive a range of doses of AG-181 or placebo, orally, once on Day 1. AG-181 will be given under fasted conditions.

    Drug: AG-181 · Drug: Placebo

  • Experimental
    Part 2: Multiple Ascending Dose (MAD)

    Participants will receive a range of doses of AG-181 or placebo twice daily (BID) for 13 days and a single dose on Day 14 under fasted conditions.

    Drug: AG-181 · Drug: Placebo

  • Experimental
    Part 3: Food Effect - Sequence 1: AB

    Participants will receive single oral dose of AG-181 on Day 1 of Period 1 under fasted condition (A) followed by single oral dose of AG-181 on Day 1 of Period 2 under fed (high fat meal) condition (B). Each period will be separated by a washout period of 1 week.

    Drug: AG-181

  • Experimental
    Part 3: Food Effect - Sequence 2: BA

    Participants will receive a single oral dose of AG-181 on Day 1 of Period 1 under fed (high fat meal) condition (B) followed by single oral dose of AG-181 on Day 1 of Period 2 under fasted condition (A). Each period will be separated by a washout period of 1 week.

    Drug: AG-181

Interventions

  • DrugAG-181

    AG-181 tablets

  • DrugPlacebo

    AG-181 matched-placebo tablets

06

What researchers measure

Primary outcomes

  1. SAD: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to Study Drug

    Time frame: Up to Day 7

  2. MAD: Number of Participants with AEs and SAEs by Type, Severity, and Relationship to Study Drug

    Time frame: Up to Day 26

  3. Food Effect: Maximum Observed Plasma Concentration (Cmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  4. Food Effect: Area Under the Concentration-time Curve up to the Last Quantifiable Concentration (AUC0-last) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  5. Food Effect: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  6. Food Effect: Time to Reach Maximum Observed Concentration (tmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  7. Food Effect: Terminal Elimination Rate Constant (Kel) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  8. Food Effect: Terminal Elimination Half-Life (t1/2) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  9. Food Effect: Apparent Oral Clearance (CL/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  10. Food Effect: Apparent Volume of Distribution at Terminal Phase (Vz/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

Secondary outcomes

  1. SAD: Maximum Observed Plasma Concentration (Cmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  2. SAD: Time to Reach Maximum Observed Concentration (tmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  3. SAD: Terminal Elimination Rate Constant (Kel) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  4. SAD: Terminal Elimination Half-Life (t1/2) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  5. SAD: Area Under the Concentration-time Curves (AUCs) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  6. SAD: Apparent Oral Clearance (CL/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  7. SAD: Apparent Volume of Distribution at Terminal Phase (Vz/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 4

  8. SAD: Renal Clearance (CLR) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  9. SAD: Total Percent of AG-181 Dose Excreted Unchanged in Urine (Fet%)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  10. SAD: Percent of AG-181 Dose Excreted Unchanged in Urine Between Time 1 and Time 2 (Fet1-t2%)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  11. SAD: Cumulative Amount of AG-181 Drug Excreted in Urine (Ae0-t)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  12. SAD: Amount of AG-181 Drug Excreted in Urine Between Time 1 and Time 2 (Aet1-t2)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  13. MAD: Maximum Observed Plasma Concentration (Cmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  14. MAD: Time to Reach Maximum Observed Concentration (tmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  15. MAD: Terminal Elimination Rate Constant (Kel) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  16. MAD: Terminal Elimination Half-Life (t1/2) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  17. MAD: Area Under the Concentration-time Curve (AUC) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  18. MAD: Apparent Oral Clearance (CL/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  19. MAD: Apparent Volume of Distribution at Terminal Phase (Vz/F) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  20. MAD: Time to Maximum Observed Plasma Concentration at Steady State (Cmax_ss) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 17

  21. MAD: Accumulation Ratio for Cmax (RA_Cmax) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 14

  22. MAD: Accumulation Ratio for Area Under the Concentration-time Curve (RA_AUC) of AG-181

    Time frame: Predose and multiple time points postdose from Day 1 to Day 14

  23. Food Effect: Number of Participants with AEs and SAEs by Type, Severity, and Relationship to Study Drug

    Time frame: Up to Day 7

07

Study locations

1 site
  • ICON 1255 East 3900 South
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Oct 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Feb 29, 2024
StartActual
Feb 20, 2024
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286033
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Feb 20, 2024
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Last update
Dec 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion